-
Uncategorized2 months ago
Revolution Medicines threatens to sue Erasca over patent, efficacy claims
Revolution Medicines threatens to sue Erasca over patent, efficacy claims
-
Uncategorized2 months agoTrump administration warns against using federal dollars on fentanyl test strips
The Trump administration is doubling down on its opposition to harm reduction services for people who use illicit drugs. In an open letter on April 24,...
-
Uncategorized2 months ago
Utah doctors demand suspension of Doctronic AI program
Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications. The...
-
Uncategorized2 months ago
Anticancer Strategy Targets Defense Mechanism in Senescent Cells
Scientists headed by a team at MRC Laboratory of Medical Sciences (LMS) and Imperial College London have found that a new set of drugs can exploit...
-
Uncategorized2 months agoOruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
-
Uncategorized2 months agoThe structural data bottleneck in AI antibody discovery
Dan Benjamin, Co-Founder & Chief Technology Officer of Immuto Scientific, examines why limited antibody–antigen co-structure datasets may be constraining AI model performance—and how high-throughput structural generation...
-
Uncategorized2 months ago
Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next
Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially...
-
Uncategorized2 months ago
Thermo Fisher sells microbiology biz; Ligand to buy XOMA
Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of...
-
Uncategorized2 months agoMonoclonal Antibodies: Unlocking Cost and Efficiency Gains in Downstream Processing
Register Now Kristina Pleitt Senior Staff ScientistThermo Fisher Scientific View Bio Panelist Kristina Pleitt Kristina Pleitt is a senior staff scientist at Thermo Fisher Scientific with...
-
Uncategorized2 months ago
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
